PMID- 25095531
OWN - NLM
STAT- MEDLINE
DCOM- 20140909
LR  - 20151119
IS  - 0890-9016 (Print)
IS  - 0890-9016 (Linking)
DP  - 2013
TI  - Post-transplant development of C1q-positive HLA antibodies and kidney graft 
      survival.
PG  - 367-75
AB  - The development of de novo human leukocyte antigen (HLA) donor specific 
      antibodies (DSA), detected by both cytotoxic or solid phase assays, was 
      considered the major risk factor for allograft failure in kidney transplantation. 
      However, it was shown that not all patients with persistent production of DSA 
      suffered loss of their grafts. Modified Luminex-Single Antigen assays, able to 
      identify C1q-fixing antibodies, represent a new strategy in assessing the 
      clinical relevance of detected DSA. This study demonstrated that C1q-fixing 
      capability of de novo DSA is a clinically relevant marker of worse outcome and 
      inferior graft survival in kidney transplantation. In fact, our findings 
      evidenced a very low graft survival only in the patients who developed DSA able 
      to fix C1q during post-transplant course, while patients producing C1q-negative 
      DSA had good graft survival, which was comparable to that found in our previous 
      study for DSA-negative patients. Moreover, anti-HLA class II antibodies had a 
      higher incidence than anti-HLA class I, and the ability to fix C1q was 
      significantly more frequent among anti-DQ DSA than anti-DR DSA. Monitoring of de 
      novo C1q-DSA production represents a useful, non-invasive tool for risk 
      stratification and prediction of graft outcome in kidney transplantation.
FAU - Piazza, Antonina
AU  - Piazza A
FAU - Poggi, Elvira
AU  - Poggi E
FAU - Ozzella, Giuseppina
AU  - Ozzella G
FAU - Adorno, Domenico
AU  - Adorno D
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Clin Transpl
JT  - Clinical transplants
JID - 8812419
RN  - 0 (Biomarkers)
RN  - 0 (HLA Antigens)
RN  - 0 (Isoantibodies)
RN  - 80295-33-6 (Complement C1q)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Biomarkers/blood
MH  - Complement C1q/*immunology
MH  - Female
MH  - Graft Rejection/epidemiology/immunology
MH  - Graft Survival/*immunology
MH  - HLA Antigens/*immunology
MH  - Humans
MH  - Immunoassay/*methods
MH  - Isoantibodies/blood/*immunology
MH  - *Kidney Transplantation/statistics & numerical data
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Sensitivity and Specificity
MH  - Young Adult
EDAT- 2013/01/01 00:00
MHDA- 2014/09/10 06:00
CRDT- 2014/08/07 06:00
PHST- 2014/08/07 06:00 [entrez]
PHST- 2013/01/01 00:00 [pubmed]
PHST- 2014/09/10 06:00 [medline]
PST - ppublish
SO  - Clin Transpl. 2013:367-75.